040 68334455
WhatsApp
Patient Portal
Home Care
Dr Madala Ravi Krishna
Area of Specialization : Medical Oncology, Hemato Oncology & Cellular Therapy, Bone Marrow Transplantation
Doctor Designation : Senior Consultant, Lead Medical & Hemato-Oncologist, Bone Marrow & Cellular Therapy Physician
Medical Qualifications : MD, DM (Medical Oncology)
Experience : 10+ Years
Practicing Location : Financial District
Languages Spoken : తెలుగు, English, हिंदी
Consultation Fee : ₹1000
Current Work Location
Medicover Hospital, Myscape Rd, Beside The District Building, Financial District, Nanakramguda, Telangana 500032
Timings: Mon to Sat 9 AM - 4 PM
Info
Dr. Madala Ravi Krishna is a Senior Consultant, Lead Medical & Hemato-Oncologist, and Bone Marrow & Cellular Therapy Physician at Medicover Hospitals, Financial District, Hyderabad. He has over 10 years of experience in diagnosing and treating different types of cancer. Dr. Ravi Krishna is known for providing advanced and patient-focused cancer care.
He specializes in the treatment of blood cancers, including lymphoma, leukemia, and multiple myeloma. He also treats lung cancer, gastrointestinal cancers, and head and neck cancers. His expertise includes genetic counselling, geriatric oncology, and precision oncology, in which treatment is tailored to the patient's genetic profile.
Dr. Ravi Krishna is skilled in advanced cancer therapies, including bone marrow transplantation and CAR-T cell therapy. These treatments help patients receive personalized care and improve recovery outcomes.
Expertise & Treatments
Dr. Madala Ravi Krishna provides advanced Medical Oncology and Hemato-Oncology care in Financial District, Hyderabad, offering personalized treatment for both solid tumors and blood cancers using evidence-based therapies and modern oncology technologies.
- Medical Oncology and Hemato-Oncology specialist in Financial District, Hyderabad
- Expert management of Lymphoma, Leukemia, and Multiple Myeloma
- Comprehensive Lung Cancer treatment in Hyderabad
- Advanced Head and Neck Cancer diagnosis and management
- Specialized care in Gastrointestinal Oncology, including stomach, colon, and liver cancers
- Bone Marrow Transplantation for blood cancers and related disorders
- Advanced CAR-T Cell Therapy for selected hematological cancers
- Precision Oncology, including Targeted Therapy and Immunotherapy
- Chemotherapy and advanced systemic cancer therapies for various cancer types
- Genetic counseling for cancer risk and treatment planning
Dr. Madala Ravi Krishna is an experienced Medical Oncologist, Hematologist, Hemato-Oncologist, and Bone Marrow Transplant Physician. He specializes in diagnosing and treating cancer and blood disorders.
He completed his MBBS from Kurnool Medical College. He then pursued an MD from SVIMS. Later, he completed DM in Medical Oncology from Tata Memorial Hospital, Mumbai, one of India's leading cancer institutes.
During his training, he worked at several Tata Memorial centers. These include Mumbai, Navi Mumbai, Varanasi, and Muzaffarpur. There, he treated many complex cancer and hematology cases.
Dr. Ravi Krishna treats both solid tumors and blood cancers. His expertise includes lymphoma, leukemia, multiple myeloma, lung cancer, head and neck cancers, and gastrointestinal cancers.
He offers advanced treatments such as chemotherapy, immunotherapy, targeted therapy, bone marrow transplantation, and CAR-T cell therapy.
His clinical interests include cancer genetics, immunology, geriatric oncology, urological cancers, and precision oncology. In precision oncology, treatment plans are based on a cancer's genetic profile.
Dr. Ravi Krishna has also worked to improve access to cancer care in underserved regions. He helped establish a Medical Oncology department in Bihar. He also managed six oncology daycare centers under the Bihar State Government. These centers provide cancer treatment for patients in remote areas.
He actively participates in oncology research and medical education. He has published research papers in international journals. He has also contributed chapters to oncology textbooks.
He became the first Indian Medical Oncology resident to present an oral paper at the ASCO (American Society of Clinical Oncology) conference in Chicago, USA.
Dr. Ravi Krishna is known for his compassionate approach and evidence-based treatment. He focuses on providing advanced and personalized cancer care. He also supports patients and families throughout the treatment journey.
He is available for consultation Monday to Saturday from 9 AM to 4 PM at Medicover Hospitals, Financial District, Hyderabad. He provides expert care, including chemotherapy, immunotherapy, targeted therapy, bone marrow transplant, and CAR-T therapy.
Past Experience
- Assistant Professor - SVIMS, Tirupathi
- Assistant Professor - TATA Hospital, Mumbai
- Assistant Professor - Homi Bhabha Cancer Hospital, Varanasi
- Assistant Professor - TATA Hospital, Muzaffarpur
Awards & Achievements
- First Indian Medical Oncology resident to deliver an oral presentation at the ASCO (American Society of Clinical Oncology) Conference, Chicago, USA
Memberships
- Member - American Society of Clinical Oncology (ASCO)
- Member - European Society for Medical Oncology (ESMO)
- Member - Indian Society of Medical and Paediatric Oncology (ISMPO)
Dr. Madala Ravi Krishna has contributed to several research studies and publications in reputed international oncology journals. His research focuses on cancer treatment outcomes, immunotherapy, head and neck cancers, lung cancer, glioblastoma, and cancer care accessibility in India.
Selected Publications:
- Patil V, Abraham G, Ravikrishna M, Bhattacharjee A, Noronha V, Parekh D, Menon N, Bajpai J, Prabhash K. Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India
- Kothari R, Patil V, krishna Madala R, Singh R, Talreja VT, Pathak A, Shrirangwar S, Mandal TK, Das S, Turkar S, Pande N. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes. Cancer Letters. 2025 Jul 1;621:217702
- Bajpai J, Panda G, Ravikrishna M, Chandrasekharan A, Rekhi B, Bhargava P, Srinivas S, Laskar S, Mokal S, Khanna N, Patil V. Vascular endothelial growth factor as a potential prognosticator in Ewing Sarcoma: a tertiary care cancer center experience from India
- Choudhary J, Kumar H, Ravikrishna M, Patil VM, Prabhash K. Real-world data of use of nivolumab in platinum refractory head and neck cancers
- Kumar H, Choudhary J, Ravikrishna M, Menon NS, Patil VM, Noronha V, Prabhash K, Joshi A. Outcomes and adverse events of low-dose nivolumab in platinum refractory head and neck cancers
- Madala RK, Krishnatry R, Noronha V, Patil V, Joshi A, Menon N, Muthuluri H, Prabhash K. Neurological deterioration in a patient with lung cancer and brain metastasis. Cancer Research, Statistics, and Treatment. 2020 Jan 1;3(1):97-9
- Prathipati A, Jilla S, Subramanian BV, Madala RK. Impact of Various Prognostic Factors on Overall Survival, Disease-Free Survival and Patterns of Failure in Carcinoma Cervix: A Tertiary Care Centre Experience from South India. Indian Journal of Gynecologic Oncology. 2018 Mar;16(1):11
- Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, Bhattacharjee A, Swain M, Mathrudev V, Nawale K, Balaji A. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. Journal of Clinical Oncology. 2023 Jan:JCO-22
- Noronha V, Abraham G, Bondili SK, Rajpurohit A, Menon RP, Gattani S, Trikha M, Tudu R, Kota KK, Singh AK, Elamarthi P, Panda GS, Rai RK, Krishna MR, Chinthala SK, Shah MJ, Shah D, Tiwari A, Vora DN, Tongaonkar AH, John G, Patil A, Menon NS, Patil VM, Joshi A, Banavali S, Badwe RA, Prabhash K. COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: A questionnaire-based survey. Cancer Res Stat Treat 2021;4:211-8
- Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021 Dec;10(24):8777-8788
- Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik AD, Epari S, Jadhav M, Pathak S, Peelay Z. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. EClinicalMedicine. 2022 Jul 1;49
- Menon NS, Chatterjee A, Tonse R, Choudhary A, Mahajan A, Puranik A, Sridhar E, Pathak S, Jadhav M, Peelay Z, Walavalkar R. Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study
- Menon NS, Gupta T, Chatterjee A, Choudhary A, Puranik A, Sridhar E, Dasgupta A, Sahay A, Moiyadi A, Shetty P, Singh VK. Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma
Book Oncologist Consultation
March 2026
Frequently Asked Questions
Dr. Madala Ravi Krishna is available at Medicover Hospitals, Financial District, Hyderabad. The hospital is located at Myscape Rd, beside The District Building, Financial District, Nanakramguda, Telangana - 500032.
He is available for consultation Monday to Saturday from 9:00 AM to 4:00 PM at Medicover Hospitals, Financial District, Hyderabad.
The consultation fee at Medicover Hospitals, Financial District is ₹1000.
Appointments can be booked online through the hospital website, by calling 040-68334455, or by visiting the Medicover Hospitals reception in Financial District, Hyderabad.
Dr. Madala Ravi Krishna is a Senior Consultant and Lead Medical & Hemato-Oncologist with expertise in diagnosing and treating cancer and blood-related disorders using advanced oncology treatments.
He treats both solid tumors and hematological cancers, including lung cancer, head and neck cancers, gastrointestinal cancers, leukemia, lymphoma, and multiple myeloma.
Dr. Ravi Krishna provides advanced cancer treatments including chemotherapy, targeted therapy, immunotherapy, bone marrow transplantation, CAR-T cell therapy, and precision oncology-based treatments.
Yes. He specializes in hemato-oncology, including the treatment of leukemia, lymphoma, and multiple myeloma, along with other complex blood disorders.
Yes. Bone marrow transplantation is one of his key areas of expertise for treating certain blood cancers and hematological conditions.
CAR-T Cell Therapy is an advanced treatment where a patient's immune cells are modified to target cancer cells. Dr. Ravi Krishna offers CAR-T cell therapy for selected hematological cancers.
Precision oncology uses the genetic profile of a tumor to guide treatment decisions. Dr. Ravi Krishna provides personalized cancer treatments using targeted therapy and immunotherapy.
Yes. Patients can consult him for second opinions on cancer diagnosis, chemotherapy planning, targeted therapy, immunotherapy, and bone marrow transplant evaluation.
Yes. He specializes in geriatric oncology, offering cancer treatment plans tailored for elderly patients.
Yes. He provides genetic counseling in cancer to help assess inherited cancer risks and guide personalized treatment decisions.
Dr. Madala Ravi Krishna provides comprehensive cancer care with expertise in Medical Oncology and Hemato-Oncology, including the diagnosis and treatment of lymphoma, leukemia, and multiple myeloma. He offers advanced care for lung cancer, head and neck cancers, and gastrointestinal cancers, along with specialized treatments such as bone marrow transplantation and CAR-T cell therapy. His approach includes precision oncology using targeted therapy and immunotherapy, as well as chemotherapy and other advanced systemic cancer treatments. Dr. Ravi Krishna also provides genetic counseling for cancer risk assessment, geriatric oncology care for elderly patients, and comprehensive management of complex solid tumors and blood cancers.
Feeling unwell?
Request a callback!
